Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Jean-Sebastien Frenel

Advertisement

Articles by Jean-Sebastien Frenel

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

BySherene Loi, MD, PhD,Erica Stringer-Reasor,Jean-Sebastien Frenel,Mattea Reinisch,Ruth M. O’Regan,Michelino De Laurentiis,Yeon Hee Park,Anne O’Dea,Yen-Shen Lu,Valeria Gonzalez,Melissa Gao,Sorcha Waters,Huilin Hu,Binghe Xu
June 24th 2025

82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer

ByBarbara Pistilli,Livia Pierotti,Magali Lacroix-Triki,Cecile Vicier,Jean-Sebastien Frenel,Véronique D’Hondt,Florence Dalenc,Thomas Bachelot,Agnes Ducoulombier,Marc-Antoine Benderra,Delphine Loirat,Didier Mayeur,Ghada B. Nachabeh,Andrea Sporchia,Fumitaka Suto,Stefan Michiels,Noemie Corcos,Fernanda Mosele,Fabrice André, Guillaime Montagnac
April 28th 2025
Advertisement

Latest Updated Articles

  • 22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
    22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/​HER2− Early Breast Cancer in NATALEE

    June 24th 2025



Advertisement
Advertisement

Trending on CancerNetwork

1

Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028

2

KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS

3

Neoadjuvant BOT + BAL Yields Pathologic Responses in pMMR/dMMR Colon Cancer

4

How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?

5

Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us